Zobrazeno 1 - 10
of 52
pro vyhledávání: '"George, Zarkavelis"'
Autor:
George Zarkavelis, Anna Lea Amylidi, Nanteznta Torounidou, Melina Yerolatsite, Athanasia Keravasili, Varvara Keramisanou, Davide Mauri
Publikováno v:
Contemporary Oncology, Vol 28, Iss 1, Pp 45-50 (2024)
Externí odkaz:
https://doaj.org/article/2ef943cde1e940508545ec53cd2b0af3
Autor:
Melina Yerolatsite, Nanteznta Torounidou, Anna-Lea Amylidi, Fani Kapoulitsa, Eleftherios Kampletsas, George Zarkavelis, Davide Mauri
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 417-422 (2024)
Introduction: The introduction of immune checkpoint inhibitors (ICIs) has opened a new chapter in cancer treatment. Nevertheless, their use may result in immune-related adverse events (irAEs) with multifactorial determinants, complex mechanisms, and
Externí odkaz:
https://doaj.org/article/2d965df517914da59828fbf9df33838d
Autor:
Anna Lea Amylidi, Aristeidis Gogadis, Melina Yerolatsite, George Zarkavelis, Nanteznta Torounidou, Varvara Keramisanou, Eleftherios Kampletsas, Davide Mauri
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10509-10518 (2023)
Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 inhibitors, have become the standard of care for many cancer types. However, they induce immune-related adverse events (irAEs), including neurotoxicity and hypophysitis. The incidence an
Externí odkaz:
https://doaj.org/article/0f91f00460cc465c94fd9ce28b23b0ff
Autor:
George Zarkavelis, Davide Mauri, Fotini Karassa, Kampletsas Eleftherios, George Pentheroudakis, Alexandra Pappadaki, Leonidas Mavroeidis, Panagiotis Ntellas, Stefania Gkoura, Ioanna Gazouli
Publikováno v:
Contemporary Oncology, Vol 24, Iss 1, Pp 75-78 (2020)
With the advent of immunotherapy and with the expanding spectrum of malignancies treated with immunomodulatory agents, a new kind of adverse events has come under the spotlight. Clinicians have to be aware of immune-related adverse events and their c
Externí odkaz:
https://doaj.org/article/6401610229f14205a504ce72908b0a15
Autor:
Leonidas Mavroeidis, Amalia Vassou, George Zarkavelis, Alexandra Papadaki, Ioanna Mouzaki, Panagiotis Ntellas, Stefania Gkoura, Ioanna Gazouli, George Pentheroudakis
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 1, Pp 1-6 (2020)
Acquired hemophilia is a rare autoimmune bleeding disorder related to the production of autoantibodies that inhibit clotting factor VIII or IX. The underlying cause can be autoimmune disease, malignancy, pregnancy, or medications, but it is most comm
Externí odkaz:
https://doaj.org/article/cd4487b12c5d4c5a910cf0b86ea85167
Autor:
Konstantinos Kamposioras, Davide Mauri, Konstantinos Papadimitriou, Alan Anthoney, Nadia Hindi, Branka Petricevic, Mario Dambrosio, Antonis Valachis, Pantelis Kountourakis, Jindrich Kopecky, Cvetka Grašič Kuhar, Lazar Popovic, Nataliya P. Chilingirova, George Zarkavelis, Ramon Andrade de Mello, Natalija Dedić Plavetić, Christos Christopoulos, Bianca Mostert, John R. Goffin, Dimitiros Tzachanis, Haytham Hamed Saraireh, Fei Ma, Ida Pavese, Maria Tolia
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
IntroductionPandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support d
Externí odkaz:
https://doaj.org/article/5ef0bdb198064c2d966675fd17816dd2
Publikováno v:
SAGE Open Medical Case Reports, Vol 8 (2020)
Immune checkpoint inhibitors, such as anti-cytotoxic T-lymphocyte–associated antigen-4 and anti-programmed death-1, are a type of cancer immunotherapy approved for late-stage malignancy treatment. However, such therapies often induce immune-related
Externí odkaz:
https://doaj.org/article/823676e5ebe94b168c4d74310b090488
Autor:
Myrto Kastrisiou, George Zarkavelis, Anastasia Kougioumtzi, Prodromos Sakaloglou, Charilaos Kostoulas, Ioannis Georgiou, Anna Batistatou, George Pentheroudakis, Angeliki Magklara
Publikováno v:
Diagnostics, Vol 11, Iss 12, p 2375 (2021)
The detection of actionable mutations in tumor tissue is a prerequisite for treatment customization in patients with metastatic colorectal cancer (mCRC). Analysis of circulating tumor DNA (ctDNA) for the identification of such mutations in patients
Externí odkaz:
https://doaj.org/article/4162b900acc542d4b4cf890d4e839471
Autor:
Vassiliki Kotoula, George Pentheroudakis, Epaminontas Samantas, Dimitrios Pectasides, George Fountzilas, Georgia-Angeliki Kolliou, Kyriaki Papadopoulou, Irene Nicolaou, George Zarkavelis, Ioannis Tikas, Vasilios Karavasilis, Christos Dervenis, Ioannis Efstratiou, Dimitra Apessou, Georgia Kafiri, Triantafyllia Koletsa, Iliada Bompolaki, Grigorios Rallis, Anna Batistatou, George Glantzounis
Publikováno v:
ESMO Open, Vol 4, Iss 5 (2019)
Pancreatic cancer is one of the most fatal malignancies ranking fourth among the leading causes of cancer death with diagnosis at late stages carrying a dismal prognosis. The aim of our retrospective study was to describe the nature and the incidence
Externí odkaz:
https://doaj.org/article/ffcaeb47f67946799890418aaa49f973
Publikováno v:
ESMO Open, Vol 4, Iss Suppl 2 (2019)
Externí odkaz:
https://doaj.org/article/d741d2413ec043e382b7c1fba4f05116